Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Original Paper

Eosinophilic Granuloma of the Skull: A Retrospective Analysis

Park S.-H. · Park J. · Hwang J.-H. · Hwang S.-K. · Hamm I.-S. · Park Y.-M.

Author affiliations

Department of Neurosurgery, Kyungpook National University Hospital, Daegu, South Korea

Related Articles for ""

Pediatr Neurosurg 2007;43:97–101

Do you have an account?

Login Information





Contact Information












By signing up for MyKarger you will automatically participate in our year-End raffle.
If you Then Do Not wish To participate, please uncheck the following box.

Yes, I wish To participate In the year-End raffle And Get the chance To win some Of our most interesting books, And other attractive prizes.


I have read the Karger Terms and Conditions and agree.



Login Information





Contact Information












By signing up for MyKarger you will automatically participate in our year-End raffle.
If you Then Do Not wish To participate, please uncheck the following box.

Yes, I wish To participate In the year-End raffle And Get the chance To win some Of our most interesting books, And other attractive prizes.


I have read the Karger Terms and Conditions and agree.



To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.
Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00


Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: April 25, 2006
Accepted: August 16, 2006
Published online: March 01, 2007
Issue release date: February 2007

Number of Print Pages: 5
Number of Figures: 0
Number of Tables: 2

ISSN: 1016-2291 (Print)
eISSN: 1423-0305 (Online)

For additional information: https://www.karger.com/PNE

Abstract

Background: The authors describe 9 cases of children with eosinophilic granuloma (EG) of the skull and report on their clinical manifestations, treatment, and prognosis. Method: Nine consecutive patients were diagnosed as EG of the skull and confirmed pathologically between 1996 and 2005. In the present study, multi- and single-system Langerhans’ cell histiocytosis without skull involvement were excluded. Patients with EG of the skull were divided into two groups: (1) those with only a single bone lesion and those with (2) multiple bone lesions. Surgical removal was performed between 2 and 10 years of age (mean, 4.2 years). Results: Eight (88.9%) of the study subjects were found to have a single bone lesion at diagnosis, and 1 had multiple bone lesions. Seven patients had a painless skull mass and 2 patients had a painful skull mass. Total removal was performed in all 9 patients. Eight patients received postoperative chemotherapy or indomethacin as adjuvant therapy. Of the 8 patients who received adjuvant therapy, 4 were treated with indomethacin and the remaining 4 received methotrexate-based chemotherapy. Eight patients did not experience EG recurrence, however, 1 patient developed additional lesions 2 years after surgical excision. Conclusions: EG of the skull is a clinicopathological entity with a good outcome. However, therapies and prognoses are dependent on age at diagnosis and the number of bony involvements.

© 2007 S. Karger AG, Basel


References

  1. Bae JK, Kwon CY, Eun JP, et al: Monostotic eosinophilic granuloma of the skull. a case report. J Korean Neurosurg 1997;26:730–734.
  2. Bernstrand C, Sandstedt B, Ahstrom L, et al: Long-terum follow-up of Langerhans cell histiocytosis: 39 years’ experience at a single centre. Acta Paediatr 2005;94:1073–1084.
  3. Broadvent V, Egeler RM, Nesbit ME: Langerhans cell histiocytosis: clinical and epidemiological aspects. Br J Cancer 1994;70:S11–S16.
  4. Hand A Jr: Polyuria and tuberculosis. Arch Pediatr 1893;10:673–675.
  5. Writing Group of the Histiocyte Society: Histiocytosis syndromes in children. Lancet 1987;i:208–209.
  6. Broadbent V, Gadner H, Komp DM, Ladisch S: Histiocytosis syndromes in children. II. Approach to the clinical and laboratory evaluation of children with Langerhans cell histiocytosis. Clinical Writing Group of the Histiocyte Society. Med Pediatr Oncol 1989;17:492–495.
  7. Nezelof C, Basset F, Rousseau MF: Histiocytosis X: histiogenic arguments for a Langerhans’ cell origin. Biomedicine 1973;18:365–371.
  8. Favara BE, Feller AC, Pauli M, et al: Contemporary classification of histiocytic disorders. Med Pediatr Oncol 1997;29:157–166.
  9. Rawlings CE III, Wilkins RH: Solitary eosinophilic granuloma of the skull. Neurosurgery 1984;15:155–161.
  10. Di Nardo LJ, Wetmore RF: Head and neck manifestations of histiocytosis-X in children. Laryngoscope 1989;99:721–724.
  11. Titgemeyer C, Grois N, Minkov M, et al: Pattern and course of single-system disease in Langerhans cell histiocytosis data from the DAL-HX 83- and 90-Study. Med Pediatr Oncol 2001;37:108–114.
  12. Jubran RF, Marachelian A, Dorey F, et al: Predictors of outcome in children with Langerhans cell histiocytosis. Pediatr Blood Cancer 2005;45:37–42.
  13. Stockschlaeder M, Sucker C: Adult Langerhans cell histiocytosis. Eur J Haematol 2006;17:1–6.
  14. Fadeel B, Henter JI: Langerhans cell histiocytosis: neoplasia or unbridled inflammation? Trends Immunol 2003;24:409–410.
  15. McLean TW, Pritchard J: Langerhans cell histiocytosis and hypercalcemia: clinical response to indomethacin. J Pediatr Hematol Oncol 1996;18:318–320.
  16. Munn SE, Olliver L, Broadbent V, et al: Use of indomethacin in Langerhans cell histiocytosis. Med Pediatr Oncol 1999;32:247–249.
  17. Ben Ezra JM, Koo CH: Langerhans’ cell histiocytosis and malignancies of the M-PRE system. Am J Clin Pathol 1993;99:464–471.
  18. Bartholdy N, Thommesen P: Histocytosis X: VII. Prognostic significance of skull lesions. Acta Radiol Oncol 1983;22:125–127.
  19. Longaker MA, Frieden IJ, LeBoit PE, et al: Congenital ‘self-healing’ Langerhans cell histiocytosis: the need for long-term follow-up. J Am Acad Dermatol 1994;31:910–916.
  20. Calming U, Henter JI: Elevated ESR and thrombocytosis may be valuable markers of active disease in Langerhans cell histiocytosis. Acta Paediatr 1998;87:1085–1087.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: April 25, 2006
Accepted: August 16, 2006
Published online: March 01, 2007
Issue release date: February 2007

Number of Print Pages: 5
Number of Figures: 0
Number of Tables: 2

ISSN: 1016-2291 (Print)
eISSN: 1423-0305 (Online)

For additional information: https://www.karger.com/PNE


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.